A Phase 2/3 trial of PTG-100 in chronic pouchitis

Trial Profile

A Phase 2/3 trial of PTG-100 in chronic pouchitis

Planning
Phase of Trial: Phase II/III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs PTG 100 (Primary)
  • Indications Pouchitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 According to a Protagonist Therapeutics media release, based on the interim results (n=65) of the ulcerative colitis PROPEL study which are reviewed by independent Data Monitoring Committee (DMC), company has postponed the decision to initiate this Phase 2/3 study. PROPEL study has been discontinued by DMC.
    • 13 Mar 2018 New trial record
    • 07 Mar 2018 According to a Protagonist Therapeutics media release, the company will initiate this trial in 2018 pending a positive decision from the interim futility analysis in the ulcerative colitis PROPEL study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top